Kura Oncology missed GAAP revenue estimates in Q2 2025. Ziftomenib advanced to FDA Priority Review, hitting key clinical and regulatory milestones, with no product sales yet. Research and ...

COPENHAGEN - Ascendis Pharma A/S (NASDAQ: ASND) shares gained 2.9% after the biopharmaceutical company reported a narrower-than-expected second-quarter loss and revenue that exceeded analyst estimates ...

QNRX READ THE FULL QNRX RESEARCH REPORT FDA clears initiation of 2nd NS pivotal whole body clinical study for QRX003, CL-QRX003-002 Quoin Pharmaceuticals (NASDAQ:QNRX) reported 2Q25 results today and ...

Treatments for acromegaly, edema, HSCT-associated thrombotic microangiopathy, multiple sclerosis, and spinal muscular atrophy are under review.

Net loss per share (GAAP) was $0.62, but remained negative as the company continues to invest heavily in research and development. The pivotal Phase 2 trial for Danon disease was placed on clinical ...

Jazz Pharmaceuticals has become the first drugmaker to get FDA approval for a treatment for diffuse midline glioma with H3 ...

US FDA grants fast track designation to Dizal’s Birelentinib to treat relapsed/refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma: Shanghai, China Thursday, ...

The issue with placing it on the floodplain is that it reduces the available area for floodwaters to spread out and slow down,” one neighbor said.

A Microsoft Exit strategy isn’t just a good idea, it’s vital. It must go a long way beyond a farewell to Redmond Opinion One ...

MSU is pausing a 'transition of psychiatric services for students,' apparently in response to pushback to layoffs of staff ...

The Indoor Football League acknowledged there was a judgment error by officials in the review process on the last play of the Rattlers' 49-48 playoff loss to the San Diego Strike Force on Aug. 4 at ...

I tested Google's Gemini AI for two months to see if it could boost my output and transform my daily routine. My boss and my ...